Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer

Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer

Conditions: Breast Cancer – Infiltrating Ductal Carcinoma; HER-2 Positive Breast Cancer
Interventions: Drug: Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy
Sponsors: Legacy Health System
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 3, 2026Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments